Ophthalmic drug delivery system utilizing thermosetting gels
Patent 4474751 Issued on October 2, 1984. Estimated Expiration Date: 
May 16, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 16, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2979528 3711604 3884826 Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes Patent #: 4188373 InventorsAssigneeApplicationNo. 06/495238 filed on 05/16/1983US Classes:514/11, Monocyclic424/114, PLURAL FERMENTATES OF DIFFERENT ORIGIN (E.G., MIXTURES OF ANTIBIOTICS, ETC.)424/116, Having a known elemental analysis (e.g., antibiotic, etc.)424/78.04, Ophthalmic preparation424/85.4, Interferon424/94.3, Stabilized enzymes or enzymes complexed with nonenzyme (e.g., liposomes, etc.)514/110, Phosphorus is part of a ring514/114, Nitrogen, other than nitro or nitroso, bonded indirectly to phosphorus514/139, Phosphorus bonded directly to halogen514/152, 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI514/161, With heterocyclic compound514/171, With additional active ingredient514/179, Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)514/197, 6-position substituent contains carbocyclic ring514/199, Penicillin G per se or salt thereof (e.g., procaine pencillin G, etc.)514/203, 3-position substituent contains pyridine ring514/206, 7-position substituent contains hetero ring514/21, Produced by or extracted from animal tissue514/236.2, Three or more ring hetero atoms in the additional hetero ring514/24, S-glycoside514/249, 1,4-diazine as one of the cyclos514/253.08, Having -C(=X)-, wherein X is chalcogen, bonded directly to carbon of the hetero ring of the quinoline ring system514/263.31, With perservative, stabilizer, or an additional active ingredient514/274, Chalcogen bonded directly to pyrimidine at 2-position514/275, Nitrogen bonded directly to the 1,3-diazine at 2-position by a single bond514/291, Plural hetero atoms in the tricyclo ring system514/30, The hetero ring has exactly 15 ring carbons514/302, Ring oxygen in the bicyclo ring system514/304, Tropanes (including nor or dehydro form)514/31, The hetero ring has 20 or more ring carbons (e.g., nystatin, etc.)514/310, Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding514/312, Chalcogen attached directly to the six-membered hetero ring by nonionic bonding514/317, Additional ring containing514/327, Chalcogen bonded directly to ring carbon of the piperidine ring514/330, C=X bonded directly to the piperidine ring (X is chalcogen)514/357, Nitrogen attached indirectly to the six-membered hetero ring by nonionic bonding514/367, Bicyclo ring system having the thiazole ring as one of the cyclos514/39, Three or more saccharide radicals (e.g., neomycin, etc.)514/399, Chalcogen or nitrogen bonded indirectly to the imidazole ring by nonionic bonding514/401, 2-imidazolines514/420, Indomethacine per se or ester thereof514/439, Plural hetero atoms in the hetero ring514/445, Chalcogen bonded directly to ring carbon of the hetero ring514/45, Purines (including hydrogenated) (e.g., adenine, guanine, etc.)514/450, The hetero ring has at least seven members514/46, Adenosine or derivative514/472, The nitrogen bonded directly to the hetero ring514/478, N-C(=X)-X-C containing514/483, Plural N-C(=X)-X groups514/490, Ring attached directly to oxygen of N-C(=0)-0514/50, 2,4-diketone pyrimidine or derivative (e.g., uracil, etc.)514/530, Z contains a cyclopentyl or cyclopentene ring514/533, Compound contains two or more C(=O)O groups indirectly bonded together by only conalent bonds514/534, Z or Y radical contains a nitrogen atom514/535, The nitrogen of the Z radical is directly bonded to a benzene ring which is directly bonded to the C(=O) group514/54, Polysaccharide514/546, ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon514/561, Nitrogen other than as nitro or nitroso nonionically bonded514/569, Polycyclo ring system514/603, Nitrogen in Q514/626, Nitrogen in R514/637, Benzene ring containing514/642, Quaternary ammonium containing514/653, Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.)514/654, The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only514/788, Nitrogen containing514/912OPHTHALMICExaminersPrimary: Robinson, Douglas W.Attorney, Agent or FirmInternational ClassesA61K 9/00 (20060101)A61K 47/18 (20060101) A61K 47/16 (20060101) AbstractThis invention describes the application of selected polymers as novel drug delivery systems which use the body temperature and pH to induce a liquid to gel transition of the polymer which contains a drug or therapeutic agent therein. The goal of such a delivery system is to achieve a greater degree of bioavailability or sustained concentration of a drug.Other References
| |
